1. Home
  2. IRMD vs MLYS Comparison

IRMD vs MLYS Comparison

Compare IRMD & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo iRadimed Corporation

IRMD

iRadimed Corporation

HOLD

Current Price

$97.18

Market Cap

910.4M

Sector

Health Care

ML Signal

HOLD

Logo Mineralys Therapeutics Inc.

MLYS

Mineralys Therapeutics Inc.

HOLD

Current Price

$37.32

Market Cap

3.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IRMD
MLYS
Founded
1992
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
910.4M
3.1B
IPO Year
2014
2023

Fundamental Metrics

Financial Performance
Metric
IRMD
MLYS
Price
$97.18
$37.32
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
7
Target Price
$72.00
$47.33
AVG Volume (30 Days)
87.7K
1.6M
Earning Date
11-03-2025
11-10-2025
Dividend Yield
0.70%
N/A
EPS Growth
13.00
N/A
EPS
1.65
N/A
Revenue
$80,511,268.00
N/A
Revenue This Year
$15.17
N/A
Revenue Next Year
$10.15
N/A
P/E Ratio
$58.91
N/A
Revenue Growth
12.91
N/A
52 Week Low
$47.48
$8.24
52 Week High
$98.44
$47.65

Technical Indicators

Market Signals
Indicator
IRMD
MLYS
Relative Strength Index (RSI) 67.41 43.48
Support Level $93.06 $36.01
Resistance Level $98.37 $39.15
Average True Range (ATR) 2.42 1.81
MACD -0.38 -0.16
Stochastic Oscillator 82.45 31.53

Price Performance

Historical Comparison
IRMD
MLYS

About IRMD iRadimed Corporation

iRadimed Corp develops, manufactures, markets and distributes a Magnetic Resonance Imaging (MRI) compatible intravenous (IV) infusion pump system, and MRI compatible patient vital signs monitoring system, and accessories and services relating to them. The company provides a non-magnetic IV infusion pump system which is designed to be safe for use during MRI procedures. The MRI products of the company are sold to hospitals and acute care facilities in the United States and internationally. It generates majority revenue from United States.

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.

Share on Social Networks: